Observational Study of NovoNorm® in Subjects With Diabetes

• Status: Completed
• Trial end date: 2005-03-25
• Target enrollment: 0
• Participant gender: All

Summary

This study is conducted in Asia. The aim of this study is to review the safety and efficacy of Novonorm® (repaglinide) in post-marketing use.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Repaglinide

Criteria

Inclusion Criteria:

• Type 2 diabetes